LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.

    Elfiky, Abdo A

    Life sciences

    2020  Volume 248, Page(s) 117477

    Abstract: ... to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).: Materials and methods ... other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based ... In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp ...

    Abstract Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).
    Materials and methods: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.
    Key findings: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.
    Significance: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/chemistry ; Adenosine Monophosphate/metabolism ; Alanine/analogs & derivatives ; Alanine/chemistry ; Alanine/metabolism ; Alphacoronavirus/enzymology ; Alphacoronavirus/genetics ; Amino Acid Sequence ; Antiviral Agents/chemistry ; Antiviral Agents/metabolism ; Betacoronavirus/enzymology ; Betacoronavirus/genetics ; COVID-19 ; Catalytic Domain ; Computational Biology/methods ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Drug Repositioning/methods ; Guanosine Monophosphate/analogs & derivatives ; Guanosine Monophosphate/chemistry ; Guanosine Monophosphate/metabolism ; Guanosine Triphosphate/chemistry ; Guanosine Triphosphate/metabolism ; Humans ; Molecular Docking Simulation ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Protein Binding ; Protein Conformation, alpha-Helical ; Protein Conformation, beta-Strand ; Protein Interaction Domains and Motifs ; RNA-Dependent RNA Polymerase/antagonists & inhibitors ; RNA-Dependent RNA Polymerase/chemistry ; RNA-Dependent RNA Polymerase/metabolism ; Ribavirin/chemistry ; Ribavirin/metabolism ; SARS-CoV-2 ; Sequence Alignment ; Sequence Homology, Amino Acid ; Sofosbuvir/chemistry ; Sofosbuvir/metabolism ; Thermodynamics ; Uridine Triphosphate/chemistry ; Uridine Triphosphate/metabolism ; Viral Proteins/antagonists & inhibitors ; Viral Proteins/chemistry ; Viral Proteins/metabolism
    Chemical Substances Antiviral Agents ; IDX184 ; Viral Proteins ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Ribavirin (49717AWG6K) ; Guanosine Monophosphate (85-32-5) ; Guanosine Triphosphate (86-01-1) ; RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; Alanine (OF5P57N2ZX) ; Uridine Triphosphate (UT0S826Z60) ; Sofosbuvir (WJ6CA3ZU8B)
    Keywords covid19
    Language English
    Publishing date 2020-02-28
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 3378-9
    ISSN 1879-0631 ; 0024-3205
    ISSN (online) 1879-0631
    ISSN 0024-3205
    DOI 10.1016/j.lfs.2020.117477
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

    Elfiky, Abdo A.

    Life Sciences

    2020  Volume 248, Page(s) 117477

    Keywords General Pharmacology, Toxicology and Pharmaceutics ; General Biochemistry, Genetics and Molecular Biology ; General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 3378-9
    ISSN 1879-0631 ; 0024-3205
    ISSN (online) 1879-0631
    ISSN 0024-3205
    DOI 10.1016/j.lfs.2020.117477
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

    Elfiky, Abdo A

    Life Sci

    Abstract: ... to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS ... The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti ... AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19 ...

    Abstract AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #2799
    Database COVID19

    Kategorien

  4. Article: Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

    Elfiky, Abdo A

    Life sciences. 2020 May 01, v. 248

    2020  

    Abstract: ... to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).In this study ... for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents ... A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19 ...

    Abstract A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
    Keywords Coronavirinae ; RNA-directed RNA polymerase ; humans ; models ; sequence analysis ; China ; covid19
    Language English
    Dates of publication 2020-0501
    Publishing place Elsevier Inc.
    Document type Article
    ZDB-ID 3378-9
    ISSN 1879-0631 ; 0024-3205
    ISSN (online) 1879-0631
    ISSN 0024-3205
    DOI 10.1016/j.lfs.2020.117477
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.

    Sacramento, Carolina Q / Fintelman-Rodrigues, Natalia / Temerozo, Jairo R / Da Silva, Aline de Paula Dias / Dias, Suelen da Silva Gomes / da Silva, Carine Dos Santos / Ferreira, André C / Mattos, Mayara / Pão, Camila R R / de Freitas, Caroline S / Soares, Vinicius Cardoso / Hoelz, Lucas Villas Bôas / Fernandes, Tácio Vinício Amorim / Branco, Frederico Silva Castelo / Bastos, Mônica Macedo / Boechat, Núbia / Saraiva, Felipe B / Ferreira, Marcelo Alves / Jockusch, Steffen /
    Wang, Xuanting / Tao, Chuanjuan / Chien, Minchen / Xie, Wei / Patel, Dinshaw / Garzia, Aitor / Tuschl, Thomas / Russo, James J / Rajoli, Rajith K R / Pedrosa, Carolina S G / Vitória, Gabriela / Souza, Letícia R Q / Goto-Silva, Livia / Guimarães, Marilia Zaluar / Rehen, Stevens K / Owen, Andrew / Bozza, Fernando A / Bou-Habib, Dumith Chequer / Ju, Jingyue / Bozza, Patrícia T / Souza, Thiago Moreno L

    The Journal of antimicrobial chemotherapy

    2021  Volume 76, Issue 7, Page(s) 1874–1885

    Abstract: Background: Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly ... 2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively ... fostered as an anti-COVID-19 therapy. ...

    Abstract Background: Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity.
    Methods: SARS-CoV-2-infected Vero cells, HuH-7 cells, Calu-3 cells, neural stem cells and monocytes were used to investigate the effects of daclatasvir and sofosbuvir. In silico and cell-free based assays were performed with SARS-CoV-2 RNA and nsp12 to better comprehend the mechanism of inhibition of the investigated compounds. A physiologically based pharmacokinetic model was generated to estimate daclatasvir's dose and schedule to maximize the probability of success for COVID-19.
    Results: Daclatasvir inhibited SARS-CoV-2 replication in Vero, HuH-7 and Calu-3 cells, with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than daclatasvir, sofosbuvir alone and combined with daclatasvir inhibited replication in Calu-3 cells. Sofosbuvir and daclatasvir prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Sofosbuvir inhibited RNA synthesis by chain termination and daclatasvir targeted the folding of secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial daclatasvir in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans.
    Conclusions: Daclatasvir, alone or in combination with sofosbuvir, at higher doses than used against HCV, may be further fostered as an anti-COVID-19 therapy.
    MeSH term(s) Animals ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19 ; Carbamates ; Chlorocebus aethiops ; Humans ; Imidazoles ; Pharmaceutical Preparations ; Pyrrolidines ; RNA, Viral ; SARS-CoV-2 ; Sofosbuvir/pharmacology ; Valine/analogs & derivatives ; Vero Cells
    Chemical Substances Antiviral Agents ; Carbamates ; Imidazoles ; Pharmaceutical Preparations ; Pyrrolidines ; RNA, Viral ; Valine (HG18B9YRS7) ; daclatasvir (LI2427F9CI) ; Sofosbuvir (WJ6CA3ZU8B)
    Language English
    Publishing date 2021-04-07
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkab072
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

    Sacramento, Carolina Q. / Fintelman-Rodrigues, Natalia / Temerozo, Jairo R. / de Paula Dias Da Silva, Aline / da Silva Gomes Dias, Suelen / dos Santos da Silva, Carine / Ferreira, André C. / Mattos, Mayara / Pão, Camila R. R. / de Freitas, Caroline S. / Soares, Vinicius Cardoso / Hoelz, Lucas Villas Bôas / Fernandes, Tácio Vinício Amorim / Branco, Frederico Silva Castelo / Bastos, Mônica Macedo / Boechat, Núbia / Saraiva, Felipe B. / Ferreira, Marcelo Alves / Rajoli, Rajith K. R. /
    Pedrosa, Carolina S. G. / Vitória, Gabriela / Souza, Letícia R. Q. / Goto-Silva, Livia / Guimarães, Marilia Zaluar / Rehen, Stevens K. / Owen, Andrew / Bozza, Fernando A. / Bou-Habib, Dumith Chequer / Bozza, Patrícia T. / Souza, Thiago Moreno L.

    bioRxiv

    Abstract: Current approaches of drugs repurposing against 2019 coronavirus disease (COVID-19) have not proven ... We thus tested whether SARS-COV-2 would be susceptible these anti-HCV drugs. DCV consistently inhibited ... to further explore these agents as COVID-19 antiviral candidates. ...

    Abstract Current approaches of drugs repurposing against 2019 coronavirus disease (COVID-19) have not proven overwhelmingly successful and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major global mortality. Daclatasvir (DCV) and sofosbuvir (SFV) are clinically approved against hepatitis C virus (HCV), with satisfactory safety profile. DCV and SFV target the HCV enzymes NS5A and NS5B, respectively. NS5A is endowed with pleotropic activities, which overlap with several proteins from SARS-CoV-2. HCV NS5B and SARS-CoV-2 nsp12 are RNA polymerases that share homology in the nucleotide uptake channel. We thus tested whether SARS-COV-2 would be susceptible these anti-HCV drugs. DCV consistently inhibited the production of infectious SARS-CoV-2 in Vero cells, in the hepatoma cell line (HuH-7) and in type II pneumocytes (Calu-3), with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than DCV, SFV and its nucleoside metabolite inhibited replication in Calu-3 cells. Moreover, SFV/DCV combination (1:0.15 ratio) inhibited SARS-CoV-2 with EC50 of 0.7:0.1 μM in Calu-3 cells. SFV and DCV prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Both drugs inhibited independent events during RNA synthesis and this was particularly the case for DCV, which also targeted secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial DCV in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Doses higher than those approved may ultimately be required, but these data provide a basis to further explore these agents as COVID-19 antiviral candidates.
    Keywords covid19
    Publisher BioRxiv; WHO
    Document type Article ; Online
    DOI 10.1101/2020.06.15.153411
    Database COVID19

    Kategorien

  7. Article ; Online: The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

    Sacramento, Carolina Q. / Fintelman-Rodrigues, Natalia / Temerozo, Jairo R. / da Silva Gomes Dias, Suelen / Ferreira, Andre C. / Mattos, Mayara / Pao, Camila R. R. / de Freitas, Caroline S. / Cardoso Soares, Vinicius / Bozza, Fernando A. / Bou-Habib, Dumith Chequer / Bozza, Patricia T. / Souza, Thiago Moreno L.

    bioRxiv

    Abstract: ... individuals with 2019 Coronavirus disease (COVID-19), the lack of safety studies and limited efficiency ... acting antivirals (DAA) against hepatitis C virus (HCV), with satisfactory safety profile. In the HCV ... in especial daclatasvir, among drugs overlooked for COVID-19, that could immediately enter clinical trials. ...

    Abstract The infection by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes major public health concern and economic burden. Although clinically approved drugs have been repurposed to treat individuals with 2019 Coronavirus disease (COVID-19), the lack of safety studies and limited efficiency as well jeopardize clinical benefits. Daclatasvir and sofosbuvir (SFV) are clinically approved direct-acting antivirals (DAA) against hepatitis C virus (HCV), with satisfactory safety profile. In the HCV replicative cycle, daclatasvir and SFV target the viral enzymes NS5A and NS5B, respectively. NS5A is endowed with pleotropic activities, which overlap with several proteins from SARS-CoV-2. HCV NS5B and SARS-CoV-2 nsp12 are RNA polymerases that share homology in the nucleotide uptake channel. These characteristics of the HCV and SARS-CoV-2 motivated us to further study the activity of daclatasvir and SFV against the new coronavirus. Daclatasvir consistently inhibited the production of infectious SARS-CoV-2 virus particles in Vero cells, in the hepatoma cell line HuH-7 and in type II pneumocytes (Calu-3), with potencies of 0.8, 0.6 and 1.1 μM, respectively. Daclatasvir targeted early events during SARS-CoV-2 replication cycle and prevented the induction of IL-6 and TNF-α, inflammatory mediators associated with the cytokine storm typical of SARS-CoV-2 infection. Sofosbuvir, although inactive in Vero cells, displayed EC50 values of 6.2 and 9.5 μM in HuH-7 and Calu-3 cells, respectively. Our data point to additional antiviral candidates, in especial daclatasvir, among drugs overlooked for COVID-19, that could immediately enter clinical trials.
    Keywords covid19
    Language English
    Publishing date 2020-06-16
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2020.06.15.153411
    Database COVID19

    Kategorien

To top